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AbstrACt
Objective Intake of whole grains is associated with 
a reduced risk of cardiovascular disease (CVD). This 
evidence is also strong for bran alone, but findings about 
germ are conflicting. Our aim was to elucidate the role 
of germ in primary prevention of cardiovascular events, 
and therefore, a staple food was selected for 6 g of germ 
supplementation. This corresponds to sixfold increase in 
the global mean consumption of germ, while preserving 
the sensory proprieties of refined bread which is crucial for 
consumer’s acceptance.
Design Randomised, double-blinded, crossover, controlled 
clinical trial with 15-week follow-up comprising a 2-week 
run-in, two intervention periods of 4 weeks each and a 
5-week washout period.
setting A single centre in the north of Portugal.
Participants 55 eligible healthy adults (mean age of 34 
years and body mass index between 19 and 38 kg/m2) 
were randomly assigned.
Interventions The study consisted of two intervention 
periods including daily intake of refined wheat bread 
enriched with 6 g of wheat germ and control (non-enriched 
bread).
Outcomes Changes in fasting cholesterol and 
triglycerides, fasting and postprandial glucose, insulin 
sensitivity and C reactive protein.
results We observed no significant effect of daily intake 
of wheat germ on cholesterol and triglycerides levels, on 
postprandial glucose response and on insulin sensitivity. 
Incremental area under curve glucose and homeostasis 
model assessment for insulin resistance did not change, 
suggesting that 6 g of wheat germ have no effect on 
glucose metabolism. No effect was also observed in the 
subgroup of participants who complied with the protocol 
(n=47).
Conclusions The absence of alterations on lipid and 
glucose profiles suggests that germ up to 6 g/day may 
have no preventive effect on CVD risk. However, it is 
important to investigate other food vehicles that can 
accommodate higher doses of wheat germ in future 
studies.
trial registration number NCT02405507.
IntrODuCtIOn 
Cardiovascular diseases (CVD) remain the 
leading cause of mortality in the world, 
having accounted for 15 million of deaths in 
2015.1 Risk factors for CVD are well-identified 
and they include smoking, type 2 diabetes 
or high glucose levels, hypertension and 
elevated cholesterol levels.2 Diet is therefore 
an important modifiable risk factor for CVD 
and, within the diet, some dietary components 
may have an important preventive role.3–5 In 
this regard, cereal whole grains are a prom-
ising protective measure due to emerging 
evidence of an inverse association between 
their intake and CVD risk as shown by recent 
systematic reviews and meta-analyses.5–8 The 
role of whole grains in reducing CVD risk is 
broader: (1) by improving glucose metabo-
lism through better postprandial glucose and 
insulin responses9; and (2) by reductions in 
strengths and limitations of this study
 ► This study followed the best practices for designing, 
conducting and reporting clinical trials to support 
health claims on food products, namely random al-
location, double blinding, reporting methods to mea-
sure and maximise compliance.
 ► We used validated outcomes which are considered 
beneficial physiological effects for human health.
 ► To the best of our knowledge, this is the largest 
study to assess the impact of germ intake in human 
subjects.
 ► Although compliance was high, it is uncertain 
whether this is due to over-reporting, since there is 
no biomarker for wheat germ intake.
 ► A longer intervention period would be desired for 
evaluating an effect on lipoprotein cholesterol, 
nonetheless could have a major impact on loss to 
follow-up in this crossover study.
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plasma cholesterol levels.10 The health benefits associated 
with whole grains intake seem to be mediated by their 
high content in plant-derived redox-active compounds 
that may activate antioxidant pathways and thereby have 
anti-inflammatory proprieties.11 
Cereal whole grains are distinguished from refined 
grains by the presence of bran and germ fractions. 
These two fractions accumulate higher amounts of 
protective bioactive compounds, such as fibres, micro-
nutrients, vitamins and phytochemicals. CVD prevention 
has been associated with bran intake,7 12–15 but findings 
about germ are conflicting.7 16 Recent systematic reviews 
addressing prospective studies reported no inverse asso-
ciation between germ intake and CVD risk, in contrast 
with prior clinical trials involving high-risk groups. But 
these two types of studies report different amounts of 
germ intake. The meta-analyses of the prospective studies 
reported a low germ intake (1 g/day average ranging 
from 0.2 to 2.9 g/day),17–19 while the intervention studies 
used a daily supplementation of 20 or 30 g/day during 
the 4-week period. Specifically, these clinical trials showed 
that intake of raw wheat germ can reduce cholesterol and 
triglycerides in rats20–22 and also in hypercholesterolaemic 
and hypertriglyceridaemic humans.23 24
Dietary guidelines around the world recommend 85 g 
daily intake of whole grains,25 which contains nearly 2.6 g 
of germ. However, their daily consumption is far below 
the recommendations and consumers prefer highly 
refined products.26–28 In fact, supplementation with 
whole-grain ingredients is therefore an elegant way to 
overcome consumer’s preferences while it contributes 
for public health, as long as these ingredients are indeed 
beneficial. Clarification of the physiological effects of 
germ is needed. However, fortification of food products 
with germ is challenging because germ becomes rancid 
very rapidly due to high content in unsaturated lipids 
together with lipases and lipoxygenases,29–31 and it also 
negatively affects the sensory properties of the final food 
product.32 Thus, in order to address these specificities, 
germ stabilisation33 is necessary immediately after milling 
to inhibit enzymatic rancidity, while the percentage of 
germ in the final product should be tested whether long-
term consumer acceptance is desired.
In this context, we designed a randomised, double-
blinded, crossover, controlled clinical trial targeting the 
general population, in order to evaluate the physiological 
and metabolic effects of germ intake in a dose higher than 
the amount reported in the previous prospective studies, 
wherein no preventive CVD effect was demonstrated. The 
impact on CVD metabolic risk factors of daily consump-
tion of 100 g of refined wheat bread enriched with 6 g of 
wheat germ during 4 weeks is here presented.
MethODs
Participants
Fifty-five healthy volunteer subjects were recruited 
from the Porto metropolitan area in northern Portugal 
through public advertisements in the University and 
Faculty websites and in online newspapers. The detailed 
study protocol has been previously described.34 Briefly, 
volunteers were invited to visit our Research Unit 
(CINTESIS) for a physical examination and a brief ques-
tionnaire about their medical history and background 
diet in order to check their eligibility to participate in the 
study. Inclusion criteria included subjects aged 18 to 60 
years old, non-diabetics and non-smokers. The exclusion 
criteria included the use of medication/dietary supple-
ments, potentially interfering with this trial, not willing 
to avoid prebiotics and probiotics for the duration of the 
study, and change of dietary habits within the 4 week prior 
to screening (for instance, to start a diet high in fibre). In 
the protocol manuscript, we described sample size calcu-
lations. Briefly, we calculated the sample size for each 
individually primary outcome, taking into account the 
difference in mean change from baseline and the respec-
tive SD. The sample size of the study was determined by 
the outcome that required the highest number of partici-
pants. Accordingly, 40 participants were required to allow 
for an 80% power and 95% confidence level.34
The study protocol was approved, and all participants 
provided written informed consent. The clinical trial 
was conducted from June 2015 to October 2016, in 
accordance with ethical principles of the Declaration of 
Helsinki, international law and Good Clinical Practice 
guidelines. This study is registered in  ClinicalTrials. gov 
database, reference NCT02405507, and followed the 
CONSORT reporting guidelines (see online supplemen-
tary table S1).
Patient and public involvement
Before recruitment, volunteers that did not participate in 
the study were invited to be involved in the development 
of the bread formula used in this trial. They had no role 
in setting the research question, the outcome measures, 
the design or implementation of the study. We included 
inputs from the participants of the study, namely any 
burden associated with the procedures, throughout the 
follow-up in order to optimise their involvement and 
compliance. Participants were involved in the sensory 
evaluation of the study breads, as well as in the recruit-
ment process by encouraging others to participate. On 
publication, participants will be informed of the results of 
this study through direct email.
study design and intervention
Our study was a 15-week, randomised, double-blinded, 
crossover, controlled clinical trial. The trial comprised 
four stages: a run-in period (2 weeks), two crossover inter-
vention periods (4 weeks each) and a washout period 
between interventions (5 weeks). At the end of each stage, 
blood samples for measurement of plasma cholesterol 
(total, low-density lipoprotein (LDL) cholesterol and 
high-density lipoprotein (HDL)), triglycerides, C reactive 
protein (CRP) and postprandial glucose were collected 
from each study participant as primary outcomes. Blood 
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samples were also collected for measurement of fasting 
glucose and insulin as secondary outcomes (see online 
supplementary figure S1). Primary and secondary 
outcomes related with gastrointestinal discomfort were 
also evaluated in this trial; however, they will be reported 
later.
Participants were instructed not to change their phys-
ical activity levels, maintain their dietary habits and do 
not consume any food or dietary product supplemented 
with germ during the study. Compliance to the study 
protocol (daily consumption of bread) was monitored 
through daily self-reported questionnaire, since there is 
no biomarker for wheat germ intake. Participants were 
randomly assigned into two intervention groups (ratio 
1:1) using a computer-generated allocation sequence by 
a statistician not involved in recruitment and interven-
tion delivery. The intervention arm comprised the daily 
consumption of wheat bread (100 g) supplemented with 
wheat germ (6 g), whereas the control arm involved the 
daily intake of wheat bread (100 g) without any supple-
mentation. The bread provided to participants replaced 
their usual bread intake during meals, namely during 
breakfast or afternoon snack.
The participants and the research team were blinded to 
the study breads (intervention/control). In this regard, 
we previously tested the best formula that masked wheat 
germ supplementation, in terms of bread texture, volume 
and flavour. Moreover, the bread was delivered to each 
participant in opaque bags with a label code (A/B); only 
the outsourced company responsible for bread produc-
tion (Padaria Ribeiro Lda., Portugal) knew the corre-
spondence code. The unblinding was performed after 
the statistical analysis had been completed.
bread formulation
Control breads were prepared by mixing 6 kg refined 
wheat flour (Germen S.A., Portugal) with 3.3 L water, 
97 g of salt, 60 g of bread improver mix (Germen, S.A., 
Portugal) and 180 g of baker’s yeast. The mixture then 
fermented for 15 min at room temperature. Dough was 
divided and moulded into pieces (123 g each), and then 
placed in a fermentation chamber with 80% relative 
humidity for 60 min at 30°C. Finally, baking was done at 
190°C during 20 min. Preparation of intervention bread 
was similar to control bread; 480 g of refined wheat flour 
was replaced by raw wheat germ (Germen S.A., Portugal) 
only.
Nutrient composition of control and intervention 
breads was analysed by Silliker Portugal, S.A. (Mérieux 
Nutrisciences Corporation).
blood sampling and analysis
The outcomes variables were measured on study partic-
ipants under 12 hours overnight fasting conditions, at 
the end of (1) run-in, (2) first intervention, (3) washout 
and (4) second intervention. Accordingly, a venous 
blood sample was collected by venipuncture into serum 
separator tubes (BD Vacutainer SST II Advance, Becton, 
Dickinson and Company). For measuring glycated 
haemoglobin (HbA1c), blood was collected into tubes 
containing K2EDTA (BD Vacutainer; Becton, Dick-
inson and Company). All venous blood samples were 
centrifuged at 1377×g for 10 min at room temperature 
(CompactStar CS4; VWR), within 30 min after collection. 
A serum aliquot was immediately stored in a special cool 
transport container (at <−10°C) for insulin quantifica-
tion. All biological samples were shipped to an outsourced 
certified medical laboratory (Clínica Laboratorial de 
Guimarães, S.A., Portugal) under refrigerated conditions. 
Analysis was performed within 24 hours after collection. 
Fasting glucose, total cholesterol and triglycerides were 
measured using specific enzymatic colorimetric methods, 
whereas LDL and HDL cholesterol were quantified by the 
elimination/catalase method. Serum CRP concentrations 
were measured by latex-enhanced immunoturbidimetric 
assay. These biochemical quantifications were done with 
the automatic analyser ADVIA 1800 (Siemens Healthcare 
Diagnostics). Insulin was determined by chemilumines-
cent microparticle immunoassay method using the auto-
matic analyser Architect i2000 (Abbott Laboratories). 
The insulin resistance was estimated using the homeo-
stasis model assessment for insulin resistance (HOMA-
IR)35 36: (fasting insulin (µU/mL)×[fasting glucose (mg/
dL)÷18.01])/22.5
Regarding the postprandial glucose, four capillary blood 
samples were obtained by finger prick sampling using 
disposable lancet devices (Glucocard MX; Arkray) and a 
glucose metre. Postprandial glycaemia was measured in 
the fasting state (0) and at 30, 60 and 120 min after inter-
vention or control bread intake. The postprandial glucose 
response was expressed as the incremental area under 
curve (IAUC), by using the trapezoidal rule ignoring the 
area below the fasting baseline, as previously described.37
statistical analysis
Statistical analysis was performed using SPSS V.23 soft-
ware (SPSS, Chicago, Illinois, USA). Data from all partic-
ipants who were randomly assigned and completed an 
initial assessment were included in the intention-to-
treat statistical analysis. Additionally, an analysis was also 
performed including the participants who adhered to 
the study protocol only, namely those that completed the 
outcome measures and complied with the daily bread 
intake (assessed by daily questionnaire). Numerical data 
are expressed as means±SD, and treatment effects with 
95% CI. Statistical significance was set at a two-sided p 
value of 0.05. However, we also decided to perform an 
adjustment for multiple comparison because of the 
multiple primary outcomes analysed; thus, the type 1 
error and significance level associated with any individual 
variable difference took into account all comparisons 
performed and were ruled significant after adjusting for 
the overall false discovery rate, using the Benjamini-Hoch-
berg procedure (with q*=0.05).38
Intervention effects were calculated as the difference 
between the change during each 4-week intervention 
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period and the change during the 4-week control period. 
A linear mixed model for repeated measures, with 
compound symmetry as the covariance structure, was used 
to determine whether the intervention effects were statis-
tically significant. Compound symmetry was used, instead 
of the autoregressive or unstructured structure because 
it resulted in the best fit according to a likelihood ratio 
test. Intervention, period and sequence were included as 
fixed variables. In order to account for between subject 
variability and to adjust for any non-specific differences, 
subjects were included as random effects. We also included 
intervention–sequence interaction as a fixed effect in the 
model to assess potential carryover effects. When carry-
over was significant, we reported the estimated interven-
tion effect for each sequence and in these cases, we only 
used the first period of the crossover trial in the analysis, 
following Pocock’s recommendations.39
results
baseline characteristics
Of 68 subjects screened to assess eligibility to participate 
in the study protocol, 55 were randomly assigned: 27 to 
the intervention– control sequence and 28 to the control–
intervention sequence. Fifty-two participants completed 
an initial assessment and were included in the statistical 
analysis (figure 1). Eight individuals dropped out: three 
did not wish to continue the study for unspecified reasons, 
three declined to participate due to personal reasons (see 
figure 1) and the last two because of unrelated illness 
(gastroparesis and pneumonia). Study participants were 
healthy men and women, with a mean age of 34 years 
(range: 18–59 years), and body mass index (in kg/m2) 
between 19 and 38 (34 normal weight, 14 overweight and 
four obese). All participants had normal fasting glucose 
and normal glucose tolerance. At baseline, 42 had 
normal fasting total plasma cholesterol (<200 mg/dL), 
eight had borderline-high fasting total plasma cholesterol 
(200–239 mg/dL) and two had high fasting total plasma 
cholesterol (>240 mg/dL). Fifty participants had normal 
fasting total plasma triglycerides (<150 mg/dL) and two 
had high fasting total plasma triglycerides (200–499 mg/
dL). Test results for haemoglobin and for liver function 
showed no evidence of ill health. Baseline characteristics 
of the 52 study participants that were included in the 
intention-to-treat statistical analysis are listed in table 1.
Participant compliance
Daily questionnaires revealed good compliance to the 
study protocol. The daily consumption of bread was 
assessed and the average compliance was 92.1%±9.3 and 
did not vary depending of bread type. Intervention and 
control arm had the same percentage of compliance: 
Figure 1 Flow chart of participants through the study.
Table 1 Baseline characteristics of study participants 
included in the analysis*
Characteristics N Value
Sex, n
 Male 16
  Female 36
Age, years 52 33.67±11.69
Body weight, kg 52 66.69±11.84
BMI, kg/m2 52 23.98±3.98
Total cholesterol, mg/dL 52 173.73±32.17
HDL cholesterol, mg/dL 52 60.71±15.04
LDL cholesterol, mg/dL 52 96.15±26.33
Triglycerides, mg/dL 52 84.40±56.42
Glucose, mg/dL 52 83.87±6.44
Insulin, µU/mL 50 7.15±3.56
HOMA-IR 50 1.49±0.79
HbA1c, % 51 5.17±0.25
IAUC glucose, mg.min/dL 50 3322.24±2086.88
CRP, mg/dL 52 0.12±0.18
*Mean±SD.
CRP, C reactive protein; HbA1c, glycated haemoglobin; HDL, high-
density lipoprotein; HOMA-IR, homeostasis model assessment for 
insulin resistance; IAUC, incremental area under the curve: LDL, 
low-density lipoprotein.
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92.2%±11.1% and 92.0%±10.0, respectively (p=0.920). 
None of the participants reported adverse effects.
Composition of intervention and control breads
The content of protein and dietary fibre was higher in 
the wheat germ-enriched bread (9.6% and 7.5%, respec-
tively), whereas control bread had a higher content of 
carbohydrate and starch (5.5% and 6.0%, respectively). 
The content of fat and energy are comparable in both 
breads. As expected, the quantity of total phytosterols and 
alpha-linolenic acid was 73.3% and 41.7% higher in the 
intervention bread, respectively (table 2).
blood lipids
There was no statistically significant difference between 
wheat germ-enriched and control breads, after 4-week 
intake, for cholesterol (total, LDL and HDL) and serum 
triglycerides (table 3).
No difference was also observed for those participants 
who completed the outcome measures and complied 
with the daily bread intake between wheat germ-en-
riched bread and control bread (n=47; total cholesterol: 
p=0.797, HDL cholesterol: p=0.996, LDL cholesterol: 
p=0.665 and triglycerides: p=0.762). The same result 
was obtained when participants with normal fasting total 
plasma cholesterol and triglycerides are analysed (n=41; 
total cholesterol: p=0.981, HDL cholesterol: p=0.413, 
LDL cholesterol: p=0.833 and triglycerides: p=0.718). 
Table 2 Chemical composition of wheat germ-enriched 
and control breads per 100 g product weight
Wheat germ-
enriched bread Control bread
Energy, kJ 1154.7 1182.8
Protein, g 9.7 8.8
Fat, g 5.4 5.5
Carbohydrate, g 44.4 47.0
Dietary fibre, g 4.3 4.0
Total sugar, g 3.4 3.4
Starch, g 40.8 43.4
Total phytosterols, mg 52.0 30.0
Moisture, g 34.5 32.9
Ash, g 1.7 1.9
Fatty acid, % of total fatty acids
 14:0 0.2 0.0
 16:0 18.9 20.7
 16:1 3.3 3.7
 18:0 2.5 4.6
 18:1 n–9 14.9 16.0
 18:1 n–7 1.2 1.1
 18:2 n-6 52.9 49.8
 20:0 0.2 0.0
 18:3 n–3 5.1 3.6
 20:1 n–9 0.8 0.5
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The results were not statistically different when partici-
pants with borderline or high fasting total plasma choles-
terol were included (n=10; total cholesterol: p=0.432, 
HDL cholesterol: p=0.170, LDL cholesterol: p=0.781 and 
triglycerides: p=0.508). Statistical analysis of blood lipid 
outcomes showed no interaction between intervention 
and sequence, potentially excluding a carryover effect.
Glucose metabolism and CrP
There were no significant changes in postprandial 
glucose peak values (at 30 min) after 4-week consump-
tion of wheat germ-enriched bread (−5.13±3.03 mg/dL; 
p=0.097) or control bread (2.35±3.73 mg/dL; p=0.531), 
and neither between interventions (p=0.182). Blood 
glucose response curves for 2 hours after the intake of 
intervention and control breads are shown in figure 2.
Comparing with control, wheat germ-enriched bread 
had no significant effect on IAUC glucose, fasting insulin 
or HOMA-IR (table 3), suggesting that 6 g of wheat 
germ did not improve postprandial glycaemia or glucose 
metabolism. No differences in CRP were observed 
between wheat germ-enriched and control breads. CRP 
and glucose results are not statistically different when 
only participants who adhered to the study protocol were 
analysed (n=47; IAUC: p=0.597, insulin: p=0.709, HOMA-
IR: p=0.597, and CRP: p=0.959).
The intervention–sequence interaction was significant 
for fasting glucose (−5.73 [-10.00; −1.46], p=0.010) and 
for HbA1c (0.15 [0.07; 0.23], p<0.001), revealing the exis-
tence of a carryover effect in these two outcomes. There-
fore, the crossover design was not considered and only 
the first period was used in the analysis, following Poco-
ck’s recommendations.39 Nevertheless, no differences in 
fasting glucose or HbA1c between wheat germ-enriched 
and control breads were observed. HbA1c reflects the 
average blood glucose level in previous 2 to 3 months.40
DIsCussIOn
In the present study, we evaluated the health effects of 
wheat germ intake in 52 healthy individuals. Blood lipids 
(cholesterol and triglycerides), fasting and postpran-
dial glucose, CRP and insulin were evaluated during 
15 weeks in a randomised crossover design. The results 
presented show that the intake of 6 g/day of wheat germ 
for 4 weeks has no effect on cholesterol and triglycerides 
levels, on glucose metabolism, namely in IAUC glucose, 
and on insulin sensitivity (HOMA-IR). Thus, our findings 
strongly suggest that wheat germ by itself has no impact 
on the cardiovascular risk factors evaluated and, thus, a 
beneficial physiological effect of wheat germ up to 6 g/
day, by decreasing the risk of CVD in normal adults, is 
unlikely. Six grams of wheat germ intake per day corre-
sponds to 2.4-fold increase in the germ present in the 
daily recommendation for whole grains intake and to a 
sixfold increase in the global mean consumption of germ.
In this study, we elucidated the role of germ in the 
primary prevention of cardiovascular events, and for this, 
we tested and developed a wheat germ-enriched bread 
without compromising the nutritional status (table 2), 
texture and flavour (see online supplementary table S2). 
Importantly, besides allowing blinding and the analysis of 
the effect of added germ individually, this no-difference 
is crucial for consumer’s acceptance if this is envisioned 
as a long-term goal. Bread was chosen as vehicle for germ 
intake because it is a staple food, major contributor to 
carbohydrates intake, whereas the wheat is globally a 
staple grain. Up until now, the beneficial effect of wheat 
germ in lowering blood cholesterol and triglycerides was 
only demonstrated when used as a diet supplementation 
with 20 g24 or 30 g/day23 during 4-week periods. Incorpo-
ration of such high proportions of wheat germ in food 
products, without impairing their nutritional profiles, is 
difficult since germ changes their sensory proprieties. 
Our study is the first interventional study evaluating the 
effect of wheat germ in higher doses than the global mean 
consumption of germ and higher than the germ present 
in the recommended doses of whole grains. This interven-
tion is a randomised, double-blinded, controlled clinical 
trial that uses a functional food product as supplemen-
tation vehicle, and not a dietary supplement. Our study 
Figure 2 Mean±SEM postprandial glucose concentrations 
in response to a 100 g wheat germ-enriched bread or control 
bread, at baseline (A), and after 4 week intervention (B). No 
significant effect in the incremental area under the curve was 
observed between wheat germ-enriched and control breads 
(p=0.524).
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followed the best practices for designing, conducting and 
reporting clinical trials to support health claims on food 
products, namely random allocation, double blinding, 
reporting methods to measure and maximise compliance. 
The strength of the current study also includes the use of 
validated outcomes which are considered to be beneficial 
physiological effects for human health.34 Finally, to our 
knowledge, this is the largest study to assess the impact of 
germ intake in human subjects and, importantly, targets 
the general population instead of a high-risk group. 
The limitations of this study include the duration of the 
intervention period. Although 4 weeks is considered the 
minimal intervention for evaluating an effect on lipo-
protein cholesterol, 8 weeks would be more desirable; 
however, such intervention period in a crossover study 
could have a major impact on loss to follow-up. Second, 
the absence of a biomarker specific for germ intake is 
also a limitation; adherence was monitored through daily 
self-reported questionnaire and, though compliance with 
the study protocol was optimal, it is uncertain whether 
there was over-reporting. Third, the presence of carry-
over effects in the fasting glucose and HbA1c reduced the 
statistical power for these two outcomes, since the cross-
over design was not considered and only the first period 
was analysed. Lastly, we decided not to collect informa-
tion about diet and physical activity levels during the 
study in order to avoid changes in general participants’ 
lifestyle and dietary patterns, and this could be seen as a 
limitation.
In order to correctly inform consumers and food and 
nutrition policy makers about the benefits of supple-
menting food products with whole grain ingredients, 
there is an urgent need for clarifying the differences 
(whether any) between whole grains and bran or germ 
individually. First, adding bran or germ individually may 
not have identical physiological benefits as the whole 
grain; and, second, these two fractions alone may have 
distinct physiological effects on cardiovascular health 
promotion when compared with the whole grain.41 Germ 
of wheat was chosen due to its potential to reduce blood 
cholesterol and triglycerides concentrations, as suggested 
in previous studies.23 24 The proposed mechanisms for 
lowering plasma cholesterol include (1) the inhibition of 
pancreatic lipase activity by soluble proteins present on 
wheat germ,42 (2) the reduction in triglyceride lipolysis,43 
and (3) reduction in cholesterol absorption by the endog-
enous wheat germ phytosterols.44 However, the existing 
evidence regarding the lipid-lowering properties of wheat 
germ from previous studies is controversial. First, reduc-
tion of total cholesterol and LDL was only evaluated in 
hypercholesterolaemic individuals after diet supplemen-
tation with 20 g/day for a 4-week period. Second, daily 
ingestion of 30 g wheat germ supplement for 4 weeks 
markedly decreases (−39%) plasma triglycerides in hyper-
triglyceridaemic individuals, whereas no reduction was 
observed in the normotriglyceridaemic subgroup.23
In our study, we enrolled a moderately large and hetero-
geneous sample of participants which is representative of 
general population, with normal, borderline-high and 
high fasting total plasma cholesterol and triglycerides. 
The statistical power of this study is higher than preceding 
studies and, for that reason, smaller differences could 
be detected if they indeed existed. Thus, it is not plau-
sible that the absence of any statistical significance on 
the wheat germ-induced changes is due to the lack of 
statistical power. However, the inexistence of wheat germ 
effects reported here does not necessarily disprove the 
potential cholesterol-lowering and triglyceride-lowering 
effect described in previous studies, in particular, because 
in those studies, wheat germ was consumed in higher 
doses and by individuals at risk. In our opinion, a dose–
response analysis for wheat germ intake and lipid profile 
should be investigated in the future, for general popula-
tion and high-risk groups.
Effect of wheat germ in improving postprandial 
glycaemia or glucose metabolism was not demonstrated 
in our study, in accordance with previous studies. Earlier 
studies addressing the long-term impact of wheat germ 
on blood lipids of hypercholesterolaemic individuals did 
not observe any significant variation on fasting glucose, 
insulin, fructosamine and HbA1c24; and one single study 
with six healthy participants showed that wheat germ had 
no effect on postprandial glucose and insulin concentra-
tions.45 Even so, we decided to investigate the impact of 
wheat germ on glucose metabolism because it was recently 
suggested that intake of alpha-linolenic acid has been 
associated with lower insulin resistance46 and our wheat 
germ enriched-bread contains more 41.7% of alpha-lino-
lenic than control bread (table 2).
In summary, our goal was to demonstrate the effect of a 
staple food supplemented with wheat germ in its maximal 
concentration without compromising its sensory proper-
ties. However, the intake of 6 g/day of wheat germ does 
not contribute to reduce the cardiovascular risk factors 
plasma triglycerides, total cholesterol, LDL cholesterol, 
or increase the HDL cholesterol levels, or even improve 
glycaemic control, in a generally healthy normal popula-
tion. In order to justify an enrichment of food products 
with wheat germ as a public health approach to prevent 
CVD, the beneficial effects of wheat germ on human 
health should be investigated in other food vehicles that 
can accommodate higher doses of germ. Chemical and 
sensory proprieties of biscuits, noodles and cakes supple-
mented with increasing amounts of wheat germ (up to 
30%) have been recently analysed and improved.32 47 48 
These technological advances let us envisage that other 
food products functionalised with higher wheat germ 
content can be developed. Future studies following 
our clinical trial design are needed to elucidate if high 
amounts of daily intake of wheat germ are effective in 
reducing CVD risk.
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